Ironwood Pharmaceuticals, Inc. (IRWD) key performance indicators and operating metrics (10 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP Net Income (Loss) Per Share Diluted | 0.24 USD_per_share | FY2026-Q1 |
| Collaboration Revenue Related to Ironwood Share of LINZESS United States Net Profits | 104.2M | FY2026-Q1 |
| LINZESS United States Net Sales | 272.5M | FY2026-Q1 |
| LINZESS United States Commercial Margin | 76.00 percent | FY2026-Q1 |
| Total LINZESS Prescription Demand | 56M | FY2026-Q1 |
| Net Profit for LINZESS United States Brand Collaboration | 204.7M | FY2026-Q1 |
| Non-GAAP Net Income (Loss) | 40.95M | FY2026-Q1 |
| Extended Unit Prescription Demand Year-Over-Year Growth Rate | 5.00 percent | FY2026-Q1 |
| Non-GAAP Net Income (Loss) Per Share | -0.01 USD_per_share | FY2025-Q4 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 81.81M | FY2025-Q3 |
Back to IRWD overview · IRWD earnings · IRWD holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.